O-GlcNAcase inhibitors as potential therapeutics for the treatment of Alzheimer’s disease and related tauopathies: analysis of the patent literature

References

• Torres CR, Hart GW. Topography and polypeptide distribution of terminal N-acetylglucosamine residues on the surfaces of intact. Evidence for O-linked GlcNAclymphocytes. J Biol Chem. 1984;259(5):3308–3317.
   PubMed Web of Science ®Google Scholar
• Holt GD, Hart GW. The subcellular distribution of terminal N-acetylglucosamine moieties. Localization of a novel protein-saccharide linkage, O-linked GlcNAc. J Biol Chem. 1986;261(17):8049–8057.
   PubMed Web of Science ®Google Scholar
• Wells L, Vosseller K, Hart GW. Glycosylation of nucleocytoplasmic proteins: signal transduction and O-GlcNAc. Science. 2001;291(5512):2376–2378.
   PubMed Web of Science ®Google Scholar
• Gao Y, Wells L, Comer FI, et al. Dynamic O-glycosylation of nuclear and cytosolic proteins: cloning and characterization of a neutral, cytosolic beta-N-acetylglucosaminidase from human brain. J Biol Chem. 2001;276(13):9838–9845.
   PubMed Web of Science ®Google Scholar
• Wells L, Gao Y, Mahoney JA, et al. Dynamic O-glycosylation of nuclear and cytosolic proteins: further characterization of the nucleocytoplasmic beta-N-acetylglucosaminidase, OGlcNAcase. J Biol Chem. 2002;277(3):1755–1761.
   PubMed Web of Science ®Google Scholar
• Hanover JA, Krause MW, Love DC. Bittersweet memories: linking metabolism to epigenetics through O-GlcNAcylation. Nat Rev Mol Cell Biol. 2012;13(5):312–321.
   PubMed Web of Science ®Google Scholar
• Bond MR, Hanover JA. A little sugar goes a long way: the cell biology of O-Glc NAc. J Cell Biol. 2015;208(7):869–880.
   PubMed Web of Science ®Google Scholar
• Müller R, Jenny A, Stanley P. The EGF repeat-specific O-GlcNAc-transferase Eogt interacts with notch signaling and pyrimidine metabolism pathways in Drosophila. PLoS ONE. 2013;8(5):e62835.
   PubMed Web of Science ®Google Scholar
• Drougat L, Olivier-Van Stichelen S, Mortuaire M, et al. Characterization of O-GlcNAc cycling and proteomic identification of differentially O-GlcNAcylated proteins during G1/S transition. Biochim Biophys Acta. 2012;1820 (12); 1839–1848.
   PubMed Web of Science ®Google Scholar
• Zachara NE, Hart GW. O-GlcNAc modification: a nutritional sensor that modulates proteasome function. Trends Cell Biol. 2004;14(5):218–221.
   PubMed Web of Science ®Google Scholar
• Vosseller K, Wells L, Lane MD, et al. Elevated nucleocytoplasmic glycosylation by O-GlcNAc results in insulin resistance associated with defects in Akt activation in 3T3–L1 adipocytes. Proc Natl Acad Sci U S A. 2002;99(8):5313–5318.
   PubMed Web of Science ®Google Scholar
• Arias EB, Kim J, Cartee GD. Prolonged incubation in PUGNAc results in increased protein O-linked glycosylation and insulin resistance in rat skeletal muscle. Diabetes. 2004;53(4):921–930.
   PubMed Web of Science ®Google Scholar
• Lagerlöf O, Slocomb JE, Hong I, et al. The nutrient sensor OGT in PVN neurons regulates feeding. Science. 2016;351(6279):1293–1296.
   PubMed Web of Science ®Google Scholar
• Lehman DM, Fu D-J, Freeman AB, et al. A single nucleotide polymorphism in MGEA5 encoding O-GlcNAc-selective N-acetyl-beta-D- Glucosaminidase is associated with Type 2 diabetes in Mexican Americans. Diabetes. 2005;54(4):1214–1221.
   PubMed Web of Science ®Google Scholar
• Ma J, Hart GW. Protein O-GlcNAcylation in diabetes and diabetic complications. Expert Rev Proteomics. 2013;10(4):365–380.
   PubMed Web of Science ®Google Scholar
• Zachara NE. The roles of O-linked β-N-acetylglucosamine in cardiovascular physiology and disease. Am J Physiol Heart Circ Physiol. 2012;302(10):H1905–H1918.
   PubMed Web of Science ®Google Scholar
• Ferrer CM, Sodi VL, Reginato MJ. O-GlcNacylation in cancer biology: linking metabolism and signaling. J Mol Biol. 2016;428(16):3282–3294.
   PubMed Web of Science ®Google Scholar
• Singh JP, Zhang K, Wu J, et al. O-GlcNAc signaling in cancer metabolism and epigenetics. Cancer Lett. 2015;356(2):244–250.
   PubMed Web of Science ®Google Scholar
• Yuzwa SA, Vocadlo DJ. OGlcNAc and neurodegeneration: biochemical mechanism and potential roles in Alzheimer’s disease and beyond. J Chem Soc Rev. 2014;43(19):6839–6858.
   PubMed Web of Science ®Google Scholar
• Ryan P, Xu M, Davey AK, et al. O-GlcNAc modification protects against protein misfolding and aggregation in neurodegenerative disease. ACS Chem Neurosci. 2019;10(5):2209–2221.
   PubMed Web of Science ®Google Scholar
• Roquemore EP, Chevrier MR, Cotter RJ, et al. Dynamic O-GlcNAcylation of the small heat shock protein αB-Crystallin†. Biochemistry. 1996;35(11):3578–3586.
   PubMed Web of Science ®Google Scholar
• Chou CF, Smith AJ, Omary MB. Characterization and dynamics of O-linked glycosylation of human cytokeratin 8 and 18. J Biol Chem. 1992;267(6):3901–3906.
   PubMed Web of Science ®Google Scholar
• Haltiwanger RS, Holt GD, Hart GW. Enzymatic addition of O-GlcNAc to nuclear and cytoplasmic proteins. Identification of a uridine diphospho-N-acetylglucosamine: peptideβ-N-acetylglucosaminyltransferase. J Biol Chem. 1990;265(5):2563–2568.
   PubMed Web of Science ®Google Scholar
• Kreppel L, Blomberg M, Hart G. Dynamic glycosylation of nuclear and cytosolic proteins. Cloning and characterization of a unique O-GlcNAc transferase with multiple tetra-tricopeptide repeats. J Biol Chem. 1997;272(14):9308–9315.
   PubMed Web of Science ®Google Scholar
• Lubas W, Frank D, Krause M, et al. O-Linked GlcNAc transferase is a conserved nucleocytoplasmic protein containing tetratricopeptide repeats. J Biol Chem. 1997;272(14):9316–9324.
   PubMed Web of Science ®Google Scholar
• Braidman I, Carroll M, Dance N, et al. Characterisation of human N-acetyl-β-hexosaminadase C. FEBS Lett. 1974;41(2):181–184.
   PubMed Web of Science ®Google Scholar
• Dong DL, Hart GW. Purification and characterization of an OglcNAc selective N-acetyl-β-D-glucosaminidase from rat spleen cytosol. J Biol Chem. 1994;269(30):19321–19330.
   PubMed Web of Science ®Google Scholar
• Heckel D, Comtesse N, Brass N, et al. Novel immunogenic antigen homologous to hyaluronidase in meningioma. Hum Mol Genet. 1998;7(12); 1859–1872.
   PubMed Web of Science ®Google Scholar
• Ma J, Hart GW. O-GlcNAc profiling: from proteins to proteomes. Clin Proteomics. 2014;11(1):8.
   PubMedGoogle Scholar
• Vocadlo DJ. O-GlcNAc processing enzymes: catalytic mechanisms, substrate specificity, and enzyme regulation. Curr Opin Chem Biol. 2012;16(5–6):488–497.
   PubMed Web of Science ®Google Scholar
• Comtesse N, Maldener E, Meese E. Identification of a nuclear variant of MGEA5, a cytoplasmic hyaluronidase and a beta-N-acetylglucosaminidase. Biochem Biophys Res Commun. 2001;283(3):634–640.
   PubMed Web of Science ®Google Scholar
• Schimpl M, Schüttelkopf AW, Borodkin VS, et al. Human OGA binds substrates in a conserved peptide recognition groove. Biochem J. 2010;432(1–7):2010.
   Google Scholar
• Rao FV, Dorfmueller HC, Villa F, et al. Insights into the mechanism and inhibition of eukaryotic O-GlcNAc hydrolysis. EMBO J. 2006;25(7):1569–1578.
   PubMed Web of Science ®Google Scholar
• Macauley MS, Whitworth GE, Debowski AW, et al. O-GlcNAcase uses substrate-assisted catalysis: kinetic analysis and development of highly selective mechanism-inspired inhibitors. J Biol Chem. 2005;280(27):25313–25322.
   PubMed Web of Science ®Google Scholar
• Cetinbas N, Macauley MS, Stubbs KA, et al. Identification of Asp 174 and Asp 175 as the key catalytic residues of human O-GlcNAcase by functional analysis of site-directed mutants. Biochemistry. 2006;45(11):3835–3844.
   PubMed Web of Science ®Google Scholar
• Herr R, Jahnke HK, Argoudelis AD. Structure of streptozotocin. J Am Chem Soc. 1967;89(18):4808–4809.
   PubMed Web of Science ®Google Scholar
• Roos MD, Xie W, Su K. et al. Streptozotocin, an analog of N-acetylglucosamine, blocks the removal of O-GlcNAc from intracellular proteins. Proc Assoc Am Physicians. 1998;110(5):422–432.
   PubMedGoogle Scholar
• Gao Y, Parker GJ, Hart GW. Streptozotocin-induced beta-cell death is independent of its inhibition of O-GlcNAcase in pancreatic Min6 cells. Arch Biochem Biophys. 2000;383(2):296–302.
   PubMed Web of Science ®Google Scholar
• Horsch M, Hoesch L, Vasella A, et al. N-acetylglucosaminono-1,5-lactone oxime and the corresponding (phenylcarbamoyl)oxime. Novel and potent inhibitors of beta-N-acetylglucosaminidase. Eur J Biochem. 1991;197(3):815–818.
   PubMedGoogle Scholar
• Vocadlo DJ, Gao Z, Gao Z, et al. NAG-thiazoline, An N-Acetyl-β-hexosaminidase inhibitor that implicates acetamido participation. J Am Chem Soc. 1996;118(28):6804–6805.
   Web of Science ®Google Scholar
• Whitworth GE, Macauley MS, Stubbs KA, et al. Analysis of PUGNAc and NAG-thiazoline as transition state analogues for human O-GlcNAcase: mechanistic and structural insights into inhibitor selectivity and transition state poise. J Am Chem Soc. 2007;129(3):635–644.
   PubMed Web of Science ®Google Scholar
• Yuzwa SA, Macauley MS, Heinonen JE, et al. A potent mechanism-inspired O-GlcNAcase inhibitor that blocks phosphorylation of tau in vivo. Nat Chem Biol. 2008;4(8):483.
   PubMed Web of Science ®Google Scholar
• Dorfmueller HC, Borodkin VS, Schimpl M, et al. GlcNAcstatin: a picomolar, selective O-GlcNAcase inhibitor that modulates intracellular O-GlcNAcylation levels. J Am Chem Soc. 2006;128(51):16484–16485.
   PubMed Web of Science ®Google Scholar
• Bergeron-Brlek M, Goodwin-Tindall J, Cekic N, et al. A convenient approach to stereoisomeric iminocyclitols: generation of potent brain-permeable OGA inhibitors. Angew Chem Int Ed. 2015;54(51):15429–15433.
   PubMed Web of Science ®Google Scholar
• Elsen NL, Patel SB, Ford RE, et al. Insights into activity and inhibition from the crystal structure of human OGlcNAcase. Nat Chem Biol. 2017;13(6):613–615.
   PubMed Web of Science ®Google Scholar
• Roth C, Chan S, Offen WA, et al. Structural and functional insight into human O-GlcNAcase. Nat Chem Biol. 2017;13(6):610–612.
   PubMed Web of Science ®Google Scholar
• Li B, Li H, Lu L, et al. Structures of human OGlcNAcase and its complexes reveal a new substrate recognition mode. Nat Struct Mol Biol. 2017;24(4):362–369.
   PubMed Web of Science ®Google Scholar
• Akimoto Y, Comer FI, Cole RN, et al. Localization of the O-GlcNAc transferase and O-GlcNAc- modified proteins in rat cerebellar cortex. Brain Res. 2003;966(2):194–205.
   PubMed Web of Science ®Google Scholar
• Liu K, Paterson AJ, Zhang F, et al. Accumulation of protein O-GlcNAc modification inhibits proteasomes in the brain and coincides with neuronal apoptosis in brain areas with high O-GlcNAc metabolism. J Neurochem. 2004;89(4):1044–1055.
   PubMed Web of Science ®Google Scholar
• Liu Y, Li X, Yu Y, et al. Developmental regulation of protein O-GlcNAcylation, O-GlcNAc transferase, and O-GlcNAcase in mammalian brain. PLoS ONE. 2012;7(8):e43724.
   PubMed Web of Science ®Google Scholar
• Khidekel N, Ficarro SB, Peters EC, et al. Exploring the O-GlcNAc proteome: direct identification of O-GlcNAc-modified proteins from the brain. Proc Natl Acad Sci U.S.A. 2004;101(36):13132–13137.
   PubMed Web of Science ®Google Scholar
• Lagerlöf O. O-GlcNAc cycling in the developing, adult and geriatric brain. J Bioenerg Biomembr. 2018;50:241–261.
   PubMed Web of Science ®Google Scholar
• Marshall S, Bacote V, Traxinger RR. Discovery of a metabolic pathway mediating glucose-induced desensitization of the glucose transport system. Role of hexosamine biosynthesis in the induction of insulin resistance. J Biol Chem. 1991;266(8):4706–4712.
   PubMed Web of Science ®Google Scholar
• Liu F, Iqbal K, Grundke-Iqbal I, et al. O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer’s disease. Proc Natl Acad Sci U.S.A. 2004;101(29):10804–10809.
   PubMed Web of Science ®Google Scholar
• Jack CR, Knopman DS, Jagust WJ, et al. Update on hypothetical model of Alzheimer’s disease biomarkers. Lancet Neurol. 2013;12(2):207–216.
   PubMed Web of Science ®Google Scholar
• Iqbal K, Liu F, Gong C-X. Tau and neurodegenerative disease: the story so far. Nat Rev Neurol. 2016;12:15–27.
   PubMed Web of Science ®Google Scholar
• Lee VM, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. Annu Rev Neurosci. 2001;24(1):1121–1159.
   PubMedGoogle Scholar
• Arnold CS, Johnson GVW, Cole RN, et al. The microtubule-associated protein tau is extensively modified with O-linked N-acetylglucosamine. J Biol Chem. 1996;271(46):28741–28744.
   PubMed Web of Science ®Google Scholar
• Liu F, Shi J, Tanimukai H, et al. Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer’s disease. Brain. 2009;132(7):1820–1832.
   PubMedGoogle Scholar
• Yuzwa SA, Vocadlo DJ. O-GlcNAc and neurodegeneration: biochemical mechanisms and potential roles in Alzheimer’s disease and beyond. Chem Soc Rev. 2014;43(19):6839–6858.
   PubMed Web of Science ®Google Scholar
• Yuzwa SA, Shan X, Macauley MS, et al. Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation. Nat Chem Biol. 2012;8(4):393–399.
   PubMed Web of Science ®Google Scholar
• Hart GW, Slawson C, Ramirez-Correa G, et al. Cross talk between O-GlcNAcylation and phosphorylation: roles in signaling, transcription, and chronic disease. Annu Rev Biochem. 2011;80(1):825–858.
   PubMedGoogle Scholar
• van der Laarse SAM, Leney AC, Heck AJR. Crosstalk between phosphorylation and O-Glc NA cylation: friend or foe. FEBS J. 2018;285(17):3152–3167.
   PubMed Web of Science ®Google Scholar
• Di Domenico F, Lanzillotta C, Tramutola A. Therapeutic potential of rescuing protein O-GlcNAcylation in tau-related pathologies. Expert Rev Neurother. 2019;19(1):1–3.
   PubMed Web of Science ®Google Scholar
• Yuzwa SA, Shan X, Macauley MS, et al. Increasing O-GlNAc slows neurodegeneration and stabilizes tau against aggregation. Nat Chem Biol. 2012;8(4):393–399.
   PubMed Web of Science ®Google Scholar
• Yuzwa SA, Macauley MS, Heinonen JE, et al. Apotent mechanism-inspired O-GlcNAcase inhibitor that blocks phosphorylation of tau in vivo. Nat Chem Biol. 2008;4(8):483–490.
   PubMed Web of Science ®Google Scholar
• Graham DL, Gray AJ, Joyce JA, et al. Increased O-GlcNAcylation reduces pathological tau without affecting its normal phosphorylation in a mouse model of tauopathy. Neuropharmacology. 2014;79:307–313.
   PubMed Web of Science ®Google Scholar
• Hastings NB, Wang X, Song L, et al. Inhibition of O-GlcNacase leads to elevation of O-GlcNac tau and reduction of tauopathy and cerebrospinal fluid tau in rTg4510 mice. Mol Neurodegener. 2017;12(1):39–55.
   PubMedGoogle Scholar
• Wang X, Smith K, Pearson M, et al. Early intervention of Tau Pathology prevents behavioral changes in the rTg4510 mouse model of tauopathy. PLoS ONE. 2018;13(4):e0195486.
   PubMed Web of Science ®Google Scholar
• Wang X, Li W, Marcus J, et al. MK-8719, a novel and selective O-GlcNAcase inhibitor that reduces the formation of pathological tau and ameliorates neurodegeneration in a mouse model of tauopathy. J Pharmacol Exp Ther. 2020;374(2):252–263.
   PubMed Web of Science ®Google Scholar
• Borghgraef P, Menuet C, Theunis C, et al. Increasing brain protein O-GlcNAcylation mitigates breathing defects and mortality of tau P301L mice. PLoS ONE. 2013;8(12):e84442.
   PubMed Web of Science ®Google Scholar
• Medina M. An overview on the clinical development of tau-based therapeutics. Int J Mol Sci. 2018;19(4):1160–1173.
   PubMed Web of Science ®Google Scholar
• Selnick HG, Hess JF, Tang C, et al. Discovery of MK-8719, a potent O-GlcNAcase inhibitor as a potential treatment for tauopathies. J Med Chem. 2019;62(22):10062–10097.
   PubMed Web of Science ®Google Scholar
• Smith SM, Struyk A, Jonathan D, et al. Early clinical results and preclinical validation of the O-GlNAcase (OGA) inhibitor MK-8719 as a novel therapeutic for the treatment of tauopathies. Alzheimer´s & Dementia. 2016;12:261.
   Google Scholar
• [cited 2020 Feb 5]. Available from:http://alectos.com/content/pipeline/.
   Google Scholar
• Quattropani A, Hantson J, Hantson J, et al. Pharmacological intervention with the novel o-GlcNacase inhibitor ASN-561 reduces pathological tau in transgenic mice. Alzheimers Dement. 2015;11(7S_Part_5):227.
   Google Scholar
• [cited 2020 Feb 12]. Available from:https://www.asceneuron.com/pipeline.
   Google Scholar
• [cited 2020 Feb 12]. Available from:https://www.asceneuron.com/news.
   Google Scholar
• [cited 2020 Feb 12]. Available from:https://clinicaltrials.gov/.
   Google Scholar
• [cited 2020 Feb 12]. Available from:https://www.lilly.com/discovery/pipeline.
   Google Scholar
• Paul S, Haskali MB, Liow JS, et al. Evaluation of a PET radioligand to image O-GlcNAcase in brain and periphery of Rhesus monkey and Knock-Out Mouse. J Nucl Med. 2019;60(1):129–134.
   PubMed Web of Science ®Google Scholar
• Vocadlo DJ, Mceachern EJ, Stubbs K, Selective glycosidase inhibitors and uses thereof. WO012106 (2010).
   Google Scholar
• Vocadlo DJ, Mceachern EJ, Selective glycosidase inhibitors and uses thereof. WO037207 (2010).
   Google Scholar
• Mceachern EJ, Sun J, Vocadlo DJ, et al. Glycosidase inhibitors and uses thereof. WO032185 (2014).
   Google Scholar
• Mceachern EJ, Sun J, Vocadlo DJ, et al. Glycosidase inhibitors and uses thereof. WO032188 (2014).
   Google Scholar
• Mceachern EJ, Vocadlo DJ, Zhou Y, et al. Glycosidase inhibitors and uses thereof WO032187 (2014).
   Google Scholar
• The formula LE = (pIC50 x 1.37)/heavy atom count, was used.
   Google Scholar
• Vocadlo DJ, Mceachern EJ, Selective glycosydase inhibitors and uses thereof, WO012107 (2010).
   Google Scholar
• Tong-Shang LI, Mceachern EJ, Vocadlo DJ, et al. Selective glycosydase inhibitors and uses thereof, WO140640 (2011).
   Google Scholar
• Li T-S, Mceachern EJ, Vocadlo DJ, et al. Selective glycosydase inhibitors and uses thereof, WO000085 (2013).
   Google Scholar
• Selnick HG, Liu K, Mceachern EJ, et al. Selective glycosydase inhibitors and uses thereof, WO025452 (2013).
   Google Scholar
• Coburn C, Liu K, Mceachern EJ, et al. Selective glycosydase inhibitors and uses thereof, WO061927 (2012).
   Google Scholar
• Coburn C, Liu K, Mceachern EJ, et al. Selective glycosydase inhibitors and uses thereof, WO061971 (2012).
   Google Scholar
• Kaul R, Mceachern EJ, Vocadlo DJ, et al. Selective glycosidase inhibitors and uses thereof, WO129651 (2012).
   Google Scholar
• Kaul R, Mceachern EJ, Mu C, et al. Selective glycosydase inhibitors and uses thereof, WO083435 (2012). Data differs from the recently published work by the Alectos Therapeutics and Merck Sharp and Dohme scientists in. J Med Chem. 2019;62(22):10062–10097.
   PubMedGoogle Scholar
• Tong-Shuang LI, Mceachern EJ, Vocadlo DJ, et al. Selective glycosidase inhibitors and uses thereof, WO000086 (2013).
   Google Scholar
• Kaul R, Mceachern EJ, Vocadlo DJ, et al. Glycosidase inhibitors and uses thereof, WO067003 (2014).
   Google Scholar
• Liu K, Mceachern EJ, Mu C, et al. Selective glycosidase inhibitors and uses thereof, WO061972 (2012).
   Google Scholar
• Chang J, Liu K, Mceachern EJ et al. Pyrano[3,2-d]thiazol derivatives and uses thereof as elective glycosidase inhibitors, WO062157 (2012).
   Google Scholar
• Chang J, Liu K, Mceachern EJ, et al. Selective glycosidase inhibitors and uses thereof, WO064680 (2012).
   Google Scholar
• Mceachern EJ, Vocadlo DJ, Zhou Y, et al. Selective glycosidase inhibitors and uses thereof, WO126091 (2012).
   Google Scholar
• Selnick HG, Li W, Hostetler E, et al. Permeable glycosidase inhibitors and uses thereof, WO168576 (2013).
   Google Scholar
• Hg S, Li W, Hostetler E, et al. Permeable glycosidase inhibitors and uses thereof, WO166654 (2013).
   Google Scholar
• Selnick HG, Liu K, Kaul R et al. Selective glycosidase inhibitors and uses thereof, WO100934 (2014).
   Google Scholar
• Vocadlo D, Mceachern EJ, Withworth G, Selective glycosidase inhibitors and uses thereof, WO025170 (2008).
   Google Scholar
• Mceachern EJ, Selnick HG, Zhou Y, Glycosidase inhibitors and uses thereof, WO106254 (2017).
   Google Scholar
• Donnely M, Qiu H, Yu H et al., Pyrano[3,2-d][1,3]thiazole as glycosidase inhibitors, WO028715 (2013).
   Google Scholar
• Yu H, Liu-Bujalski L, Johnson TL, Glycosidase inhibitors, WO159234 (2014).
   Google Scholar
• [cited 2021 May 04]. Available from:https://www.asceneuron.com/mission-history.
   Google Scholar
• Quattropanni A, Kulkarni S, Giri AG, Glycosidase inhibitors, WO030443 (2016).
   Google Scholar
• Quattropanni A, Kulkarni S, Giri AG, Glycosidase inhibitors, WO144633 (2017); (b) Quattropanni A, Kulkarni S, Giri AG, Glycosidase inhibitors, WO144639 (2017).
   Google Scholar
• Quattropanni A, Kulkarni S, Giri AG, et al. Process for the separation of enantiomers of piperazine derivatives, IN21006637 (2016).
   Google Scholar
• Quattropanni A, Kulkarni S, Giri AG, et al., Acid addition salts of piperazine derivatives, WO144637 (2017).
   Google Scholar
• Quattropanni A, Kulkarni S, Giri AG, Substituted dihydrobenzofurane glycosidase inhibitors, WO153507 (2018).
   Google Scholar
• Quattropanni A, Kulkarni S, Giri AG, Sulfoximine glycosidase inhibitors, WO153508 (2018).
   Google Scholar
• Quattropanni A, Kulkarni S, Giri AG, Annulated glycosidase inhibitors, WO037861 (2019).
   Google Scholar
• Quatroppani A, Wishart G, Kulkarni S et al. Pyrrolidine glycosidase inhibitors. WO039027 (2020).
   Google Scholar
• Quatroppani A, Wishart G, Kulkarni S, et al. Tetrahydro-benzoazepine glycosidase inhibitors. WO039028 (2020).
   Google Scholar
• Quatroppani A, Kulkarni S, Rakesh P, et al. Spirocompounds as glycosidase inhibitors. WO039029 (2020).
   Google Scholar
• Quatroppani A, Kulkarni S, Rakesh P Fused glycosidase inhibitors. WO169804 (2020).
   Google Scholar
• Bartolomé-Nebreda JM, Trabanco-Suárez AA, Martínez Viturro CM, et al. Bicyclic OGA inhibitor compounds. WO109198 (2018).
   Google Scholar
• Bartolomé-Nebreda JM, Trabanco-Suárez AA, Alcázar-Vaca MJ [1,2,4]Triazolo[1,5-a]pyrimidinyl derivatives substituted with piperidine, morpholine or piperazine as OGA inhibitors and their preparation. WO154133 (2018).
   Google Scholar
• Bartolomé-Nebreda JM, Trabanco-Suárez AA, Alcázar-Vaca MJ, et al. Monocyclic OGA inhibitor compounds. WO109202 (2018).
   Google Scholar
• Bartolomé-Nebreda JM, Trabanco-Suárez AA, Martínez Viturro CM, et al. Bicyclic OGA inhibitor compounds. WO141984 (2018).
   Google Scholar
• Martínez-Viturro CM, Trabanco AA, Royes J, et al. Diazaspirononane Nonsaccharide Inhibitors of O-GlcNAcase (OGA) for the Treatment of Neurodegenerative Disorders. J Med Chem. 2020;63(22):14017–14044.
   PubMed Web of Science ®Google Scholar
• Bartolomé-Nebreda JM, Trabanco-Suárez AA, Martínez Viturro CM, et al. Bicyclic OGA inhibitor compounds. WO243526 (2019).
   Google Scholar
• Bartolomé-Nebreda JM, Trabanco-Suárez AA, Martínez Viturro CM OGA inhibitor compounds. WO243525 (2019).
   Google Scholar
• Bartolomé-Nebreda JM, Trabanco-Suárez AA, De Lucas-Olivares AI, et al. OGA inhibitor compounds. WO243528 (2019).
   Google Scholar
• Bartolomé-Nebreda JM, Trabanco-Suárez AA, Delgado-Jiménez F, et al. OGA inhibitor compounds. WO243531 (2019).
   Google Scholar
• Bartolomé-Nebreda JM, Trabanco-Suárez AA, Martínez Viturro CM, et al. Bicyclic OGA inhibitor compounds. WO243527 (2019).
   Google Scholar
• Bartolomé-Nebreda JM, Trabanco-Suárez AA, De Lucas-Olivares AI, et al. OGA inhibitor compounds. WO243530 (2019).
   Google Scholar
• Bartolomé-Nebreda JM, Trabanco-Suárez AA, Leenaerts JE, et al. OGA inhibitor compounds. WO243533 (2019).
   Google Scholar
• Bartolomé-Nebreda JM, Trabanco-Suárez AA, Tresadern GJ, et al. OGA inhibitor compounds. WO243535 (2019).
   Google Scholar
• Dreyfus NJF, Lindsay-Scott PJ, N-[4-Fluoro-5-[[(2S,4S)-2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]-1-piperidyl]methyl]thiazol-2-yl]acetamide as OGA inhibitor. WO140299 (2018).
   Google Scholar
• NJF D, Lindsay-Scott PJ, Rathmell RE, 5-Methyl-1,3,4-oxadiazol-2-yl compounds. WO217588 (2018).
   Google Scholar
• NJF D, Faller A, 2,3-Dihydrofuro[2,3-b]pyridine compounds. WO245907 (2019).
   Google Scholar
• Dreyfus NJF, Lindsay-Scott PJ, 5-Methyl-4-fluoro-thiazol-2-yl compounds. WO028115 (2020).
   Google Scholar
• Dreyfus NJF, Lopez JE, Winneroski LL, et al. 6-Fluoro-2-methylbenzo[b]thiazol-5-yl compounds. WO068530 (2020).
   Google Scholar
• Hayashi ML, Irizzary MC, Nuthall H, Combination Therapy. WO028141 (2020).
   Google Scholar
• Genung N, Guckian KM, Vessels J, et al. O-Glycoprotein-2-acetamido-2-deoxy-3-D-glycopyranosidase inhibitors. WO178191 (2019).
   Google Scholar
• Genung N, Guckian KM, Vessels J, et al. O-Glycoprotein-2-acetamido-2-deoxy-3-D-glycopyranosidase inhibitors. WO117961 (2020).
   Google Scholar
• Genung N, Guckian KM, Vessels J, et al. Morpholinyl, piperazinyl, oxazepanyl and diazepanyl O-glycoprotein-2-acetamido-2-deoxy-3-D-glycopyranosidase inhibitors. WO061150 (2020).
   Google Scholar
• Genung N, Guckian KM, Vessels J, et al. Bicyclic ether O-glycoprotein-2-acetamido-2-deoxy-3-D-glycopyranosidase inhibitors. WO163193 (2020).
   Google Scholar
• Genung N, Guckian KM, Vessels J, et al. Azetidinyl O-glycoprotein-2-acetamido-2-deoxy-3-D-glycopyranosidase inhibitors. WO185593 (2020).
   Google Scholar
• Storer R, Tinsley JM, Wilson FX et al. Pyrrolidine derivatives as selective glycosidase inhibitors and uses thereof. WO117219 (2012).
   Google Scholar